Summit Therapeutics Inc. (NASDAQ:SMMT) disclosed that Chief Operating Officer and Chief Financial Officer Manmeet Singh acquired 50,000 shares of common stock on June 4, 2026, with a total value of $722,250. The shares were purchased at prices ranging from $14.43 to $14.46 per share. This acquisition is notable as it occurs while Summit's stock is trading near its 52-week low of $13.83. Over the past week, the stock has declined approximately 13%, reaching a current price of $14.83.
Singh executed the purchase through two separate transactions on the reporting date. Following these acquisitions, he directly owns 3,123,603 shares of Summit Therapeutics common stock. No derivative transactions were reported in connection with this activity.
The timing of this insider purchase coincides with recent analyst evaluations following the presentation of ivonescimab trial data at a medical conference. Cantor Fitzgerald has reiterated an Overweight rating on Summit Therapeutics, highlighting positive data from the Phase 3 HARMONi-6 trial conducted in China. The trial demonstrated an overall survival benefit for ivonescimab in treating first-line squamous non-small cell lung cancer.
Stifel also maintained a Buy rating and set a $45.00 price target. The firm noted the trial's achievement of a 0.66 overall survival hazard ratio, which corresponds to a four-month median survival improvement. On the other hand, Bernstein SocGen Group reiterated an Underperform rating with a $7.70 price target. The firm expressed concerns over the limited applicability of the HARMONi-6 trial results to Summit's global HARMONi-3 Phase 3 trial. Bernstein's analysis suggests a non-statistically significant overall survival trend, advising investors to consider exiting or shorting positions.
These recent developments have provided a range of perspectives for investors to consider. The stock's current trading activity and insider transactions reflect the ongoing assessment of Summit's financial positioning and market valuation. The company's $11.7 billion market cap and financial metrics continue to be analyzed for potential undervaluation, with additional insights available to subscribers.